HUTCHMED (China) (HCM) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunome (IMNM) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 37.8% versus a loss of 16.6%. Over five years, IMNM leads with a +9.7% price change compared with -57.7% for HCM. HUTCHMED (China) is the larger company by market cap ($2.38 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | IMNM |
|---|---|---|
| Share price | $13.67 | $19.31 |
| Market cap | $2.38B | $2.28B |
| 1-day change | -4.27% | +1.13% |
| YTD return | +2.55% | -10.10% |
| 1-year return | -16.60% | +37.83% |
| 5-year return | -57.68% | +9.65% |
| P/E ratio (TTM) | 136.70 | — |
| Forward P/E | 52.74 | — |
| EPS (TTM) | $0.10 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | — |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $30.06 |
| 52-week low | $9.77 | $13.49 |
| Distance from 52-week high | -16.29% | -35.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.01% | +82.29% |
| Average volume | 68.02K | 1.20M |
| Shares outstanding | 173.81M | 118.00M |
| Employees | 1,790 | 247 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed HCM by 54.4 percentage points over the past year.
- The two companies sit in different sectors: HUTCHMED (China) in Health Care and Immunome in Healthcare.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Healthcare · Biotechnology · 247 employees
HCM vs IMNM FAQ
Which is bigger, HUTCHMED (China) or Immunome?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.38B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, HCM or IMNM?
IMNM returned +37.83% over the past 12 months, compared with -16.60% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Immunome in the same industry?
No. HUTCHMED (China) is in the Health Care sector, while Immunome is in Healthcare.